Werewolf Therapeutics reports Q3 2022 net loss of $11.9M; first patient dosed in WTX-124 Phase 1/1b trial

Werewolf Therapeutics, Inc.

2022-Q3 EPS reported -$1.48

Net loss of $11.9M for Q3 2022 vs $13.8M in Q3 2021; cash and equivalents $140.5M as of Sept 30.
First patient dosed in Phase 1/1b trial of WTX-124 (IL-2 INDUKINE) as monotherapy and in combination with KEYTRUDA; initial data expected Q4 2023.
FDA cleared IND for WTX-330 (IL-12 conditionally activated molecule); Phase 1 study in immunotherapy-resistant tumors starting.
Collaboration revenue from Jazz licensing agreement was $5.0M in Q3 2022 (none in prior year); R&D expenses $13.1M.
Cash runway through at least Q2 2024, supported by existing cash, anticipated collaboration revenue, and term loan facility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Werewolf Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $5.0 million.

Period: third quarter ended September 30, 2022
Revenue: $5.0 million
Result: reported results

Exact text from the filing

sufficient to fund its operational expenses and capital expenditure requirements through at least the second quarter of 2024. • Collaboration revenue: Collaboration revenue was $5.0 million for the third quarter of 2022, compared to zero for the same period in 2021. Collaboration revenue is related to amortization of the $15.0 million upfront payment received in

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Werewolf Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001785530-22-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.